Artemisone and artemiside - potent pan-reactive antimalarial agents that also synergize redox imbalance in *P. falciparum* transmissible gametocyte stages

Dina Coertzen,[a] Janette Reader,[a] Mariëtte van der Watt,[a] Sindisiwe H. Nondaba,[a] Liezl Gibhard,[b] Lubbe Wiesner,[b] Peter Smith,[b] Sarah D'Alessandro,[c] Donatella Taramelli,[c] Ho Ning Wong,[d] Jan L. du Preez,[d] Ronald Wai Kung Wu,[e] Lyn-Marie Birkholtz,[a#] and Richard K. Haynes[d#]

Department of Biochemistry, University of Pretoria Institute for Sustainable Malaria Control, University of Pretoria, Private Bag X20, Hatfield, 0028, South Africa[a]; Division of Clinical Pharmacology, Department of Medicine, Groote Schuur Hospital, Old Main Building K45, University of Cape Town, Observatory, 7925[b]; Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Università degli Studi di Milano, Milan, Italy[c]; Center of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa[d]; Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong[e]

Running title: Redox drugs synergize in *P. falciparum* gametocytes

[#]Address correspondence: for parasite work, Lyn-Marie Birkholtz, lbirkholtz@up.ac.za and for chemistry and artemisinin work, Richard Haynes, richard.haynes@nwu.ac.za/ haynes@ust.hk

ABSTRACT

The emergence of resistance towards artemisinin combination therapies (ACTs) by the malaria parasite *Plasmodium falciparum* has the potential to severely compromise malaria control. Therefore, development of new artemisinins in combination with new drugs that impart activities towards both intraerythrocytic proliferative asexual and transmissible gametocyte stages, in particular those of resistant parasites, are urgently required. We define artemisinins as oxidant drugs through their ability to oxidize reduced flavin cofactors of flavin disulfide reductases critical for maintaining redox-homeostasis in the malaria parasite. Here we compare the activities of 10-amino artemisinin derivatives towards the asexual and gametocyte stages of *P. falciparum* parasites. Of these, artemisone and artemiside inhibited asexual and gametocyte stages, particularly stage V gametocytes in the low nM range. Further, treatment of both early and late gametocyte stages with artemisone or artemiside combined with the pro-oxidant redox partner methylene blue displays notable synergism. These data suggest that modulation of redox-homeostasis likely is an important druggable process, particularly in gametocytes, and thereby enhances the prospect of using combinations of oxidant and redox drugs for malaria control.

INTRODUCTION

Chemotherapy, coupled with vector control, has reduced malaria disease mortality by over 66% since 2000 (1). However, the emergence of drug resistance by *Plasmodium falciparum* parasites to clinically used artemisinin derivatives dihydroartemisinin (DHA), artesunate and artemether currently used in artemisinin combination therapies (ACTs) represents a crushing setback to global malaria control (2-5). Therefore, the need to develop new drugs for use in ACTs that counter the resistance and thereby supplant the combinations of current artemisinin derivatives with other antimalarial drugs becomes a particularly urgent task (6). In addition, new partner drugs other than those – amodiaquine, lumefantrine, mefloquine, piperaquine and pyronaridine – normally used in ACTs are also mandated given that reduced susceptibility of the parasite to the current partner drugs is now established (7-11). The seriousness of the problem is starkly illustrated by the rapid spread of a single mutant associated with artemisinin resistance that has also acquired resistance to piperaquine (12).

In addition to activity against asexual intraerythrocytic stages of resistant parasites, any new drug either alone or combined with another drug must also be highly active against the sexual gametocyte stages so that by blocking transmission it may inhibit the spread of the resistant phenotypes (13). This property is not manifest in current drug combinations. In the absence of resistance, ACTs such as artemether-lumefantrine, DHA-piperaquine and sulfa-doxine-pyrimethamine-artesunate are curative of intraerythrocytic asexual stage parasite infections and decrease gametocyte densities and clearance times, but are only moderately effective in clearing mature stage gametocytes (14, 15). As part of a large scale international interdisciplinary research program involving the design and development of new triple drug combinations for the treatment of malaria, tuberculosis, and toxoplasmosis, we are evaluating the

utility of combinations of oxidant (16-18) and redox (or 'pro-oxidant') drugs (19-21) coupled with a third partner drug with a different mechanism of action. The third partner drug being considered in the first instance incorporates a 4(1*H*)-quinolone scaffold (22). Quinolones are used clinically for treatment of tuberculosis (23); selected examples have acquired lead status as antimalarial drugs (24-26) and display potent dual target effects when combined with the appropriate drug partner (25). Thus, the ultimate aim is to develop compounds that when used in combination are not only effective against drug-resistant intraerythrocytic asexual stage parasites but also are highly active against the sexually differentiated transmissible gametocyte stages (13).

It is widely accepted that artemisinins undergo reductive 'bioactivation' either by heme-iron(II) or labile non-heme iron(II) to produce 'toxic' C-radicals that alkylate vital intraparasitic proteins (27-29) through chemoproteomic analyses (30-32). However, the complicated polypharmcology of these compounds may additionally be explained by defining artemisinins and other antimalarial peroxides as *oxidant* drugs. This is based on the potential inability of such radicals to act as 'alkylating' agents in the oxygen-rich essentially oxidizing environment of the intraerythrocytic parasite (18, 33, 34). Further, artemisinins are recalcitrant reaction partners for iron under biologically realistic conditions. What is clear is that intraerythrocytic parasites are oxidatively stressed (19-21, 33, 34), as reflected in the greatly increased turnover of glucose-6-phosphate dehydrogenase (G6PD) required to generate NADPH (35, 36) for reduction of flavin cofactors FAD, FMN *etc.* by glutathione reductase (GR), thioredoxin reductase (TrxR) and other flavin disulfide reductases (37). The reduced flavin cofactors provide electrons for reduction of endogenous disulfides, *e.g.* oxidized glutathione (GSSG), to the corresponding thiol required for interception of reactive oxygen species (ROS), thereby maintaining redox homeostasis (33, 38,

39). However, artemisinins rapidly oxidize such reduced flavin cofactors (Fig.1Ai) (16, 17, 39). Thus, electron supply from the reduced flavin cofactor is diverted to the artemisinin and build-up of ROS with abrogation of redox homeostasis in *P. falciparum* thereby takes place (Fig. 1B). This is compatible with the observations that activities of artemisinins against *P. falciparum* are enhanced in an oxygen enriched atmosphere (40), and that formation of ROS occurs upon treatment of malaria parasites with artemisinin (41-43). Further, it is strikingly apparent that artemisinin resistance, as associated with mutations in the *P. falciparum* Kelch13 (*Pf*K13) propeller domain and induction of dormancy of ring stage parasites as part of a complex signaling cascade reflects an enhanced inertness of the parasite to oxidative stress (3, 44). It is notable that DHA is labile under physiological conditions, yet it is modelled intact into the *P. falciparum* phosphatidylinositol-3-kinase (*Pf*PI3K) target (45). Given the structural diversity of artemisinins and synthetic peroxides that elicit potent antimalarial activities (4), the presentation of a model invoking classical inhibition by binding into an endogenous receptor site is not convincing. According to precedent for this type of target involving redox-sensitive signal transduction pathways, the nature of the inhibition may equate with generation of ROS by the artemisinin and evidently, inhibition of phosphatidylinositol-3-phosphate (PI3P) generation by ROS (46-48).

Hence, by combining an artemisinin with a redox drug, action of each should be promoted. Although several structurally disparate redox drugs are under active examination in this project, we illustrate the principle here with methylene blue (MB, Fig.1Aii) (38, 49). MB undergoes redox cycling via oxidation of its reduced conjugate leucomethylene blue (LMB) to MB by oxygen, a process that also generates ROS (50, 51). As must be closely related to the case with artemisinins, intraparasitic GR, TrxR, lipoamide dehydrogenase and others are directly

affected by MB (51, 52). MB rapidly oxidizes the reduced cofactor $FADH_2$ (53, 54) and thereby enhances consumption of NADPH associated with these reductases (38, 39, 54). Despite its relatively poor physicochemical properties (51, 54), MB has potent antimalarial activities, with a mean IC_{50} of 3.62 nM *in vitro* against asexual intraerythrocytic drug-sensitive and -resistant *P. falciparum* parasites (55). Additionally, the activity of MB against early asexual ring stage parasites (56) and especially gametocytes (57) greatly increases the potential of this drug for malaria treatment in combination with artemisinins. The overall benefit of combining an oxidant artemisinin with a redox drug is clear - the artemisinin abruptly induces oxidative stress that is then maintained or enhanced by redox cycling of the redox drug partner (Fig. 1B).

Although current clinical artemisinins are the most rapidly acting of antimalarial drugs, these are unsuitable for the artemisinin component of the planned triple drug combinations. The resistance issue aside, the drugs show variable pharmacokinetic profiles, low bioavailability (58) and, especially for DHA, elicit concerns of neurotoxicity based on established data from *in vitro* and *in vivo* studies (59-61). All are thermally and chemically fragile, and for DHA, the thermal instability engenders problems during formulation and storage (62). Therefore, emphasis has to be placed on the development of derivatives incapable of providing the active metabolite DHA common to the current clinical artemisinins. Thus, the focus here is on newer derivatives bearing amino groups at C10 referred to as 10-amino artemisinins that are readily obtained from DHA and which are optimally active against *P. falciparum in vitro* (63-66). For artemisone at least, lack of neurotoxicity has been unequivocally established (64, 67).

As the individual compounds were screened in the past against *P. falciparum* in different laboratories at different times using different methods, it is important to conduct at the same time comparative efficacy studies in order to gain a true appreciation of the optimally-active

compounds. We therefore describe here the results of such screens involving artemisone, artemiside, the 10-sulfamide (64) and 10-arylamine derivatives (63), and the new 10-piperazine and 10-phenylurea derivatives (Fig. 2). The 10-piperazine derivative attracts because it completes assessment of a series of compounds bearing a six-membered amino-heterocyclic ring attached via the nitrogen atom to C-10 as exemplified by artemisone with its thiomorpholine-*S*,*S*-dioxide ring, artemiside with its thiomorpholine ring, and the corresponding highly active morpholino derivative (68), the last whose further examination is precluded on toxicity grounds (64). Importantly, in the case of artemisone, DHA is not a product of metabolism. Metabolic profiles for the other compounds are also established wherein DHA is not produced; the results will be published elsewhere.

We describe the assessment of activities of the amino artemisinins against intraerythrocytic asexual stage parasites and early and late stage gametocytes of *P. falciparum* in accord with prerequisites for development of new antimalarial drugs. We thereupon select the best of the derivatives and examine their combination with MB as proof-of-concept for enhancing oxidative stress in the parasites, in particular as this bears on the sensitivity of gametocytes to perturbation of redox homeostasis.

RESULTS

Chemistry. Artemisone, artemiside and the 10-sulfamide were originally obtained by application of *N*-glycosylation technology to activate the hydroxyl group in DHA by conversion into the trimethylsilyl ether and thence into the β-bromide by treatment with trimethylsilyl bromide in dichloromethane (64, 68). All compounds were more economically obtained via conversion of DHA into the β-chloride via direct treatment with anhydrous hydrogen chloride in

the presence of lithium chloride in dichloromethane (65, 69). Addition of the amine nucleophile to the halide generated *in situ* provided the 10-amino artemisinin. The 10-arylamine derivative was prepared directly from DHA through activation of the hydroxyl group by a facile phase transfer process in the presence of p-fluoroaniline (63). The 10-piperazine derivative was obtained by addition of the β-bromide of DHA prepared as described above to an excess of anhydrous piperazine in dichloromethane. The most economical and experimentally facile method, especially on a larger scale, was to treat a relatively concentrated solution of DHA (0.7 M) in dichloromethane with oxalyl chloride (1.1 equiv.) to convert it into the β-chloride *in situ*, and to add the resulting solution to an excess of piperazine (Scheme 1). The 10-piperazine derivative, formed in 80% yield by the latter method, is a basic highly polar compound that could not be readily purified except by flash chromatography over silica gel and elution with a solvent combination containing triethylamine followed by crystallization from ethyl acetate. The 10-phenylurea derivative was obtained in 60% isolated yield by treatment of the 10-piperazine derivative with phenyl isocyanate in dichloromethane (Scheme 1). This nicely crystalline compound, m.p. 162-163 °C, was readily purified, is thermally relatively stable, and represents a distinct artemisinin sub-class. Spectroscopic and other information on the amino artemisinins used here are given in the Supplemental material.

Efficacy Studies

Amino artemisinins inhibit asexual parasite proliferation and metabolic activity.

The *in vitro* activities of the 10-amino artemisinins along with reference drugs artemisinin, DHA, artesunate, artemether, chloroquine (CQ) and MB were determined against drug sensitive (NF54) and drug resistant (Dd2, K1 and W2) *P. falciparum* intraerythrocytic asexual parasites using both metabolic (parasite lactate dehydrogenase pLDH) and proliferative (SYBR Green I fluorescence)

viability readouts. These two different assay platforms allowed for comparative analysis of the overall activities of the compounds towards the asexual stages. The IC_{50} values obtained for the NF54 strain with these two assay platforms were closely associated ($r^2 = 0.63$) showing good intra-assay variability with average Z-factors of 0.70 for the metabolic pLDH and 0.69 for the proliferative SYBR Green I assay. Acceptable inter-assay reproducibility with an average percentage coefficient of the variance (% CV) of 4.1% for the metabolic and 5.2% for the proliferative assay was obtained.

The 10-amino artemisinins were potently active against drug sensitive NF54 asexual parasites with IC_{50} values in the low nanomolar range (~10 nM) for both assay platforms, with the reference compounds showing similar activities (Table 1). Artemisone and artemiside were confirmed to be the most active compounds with IC_{50} values of ~2 nM (Table 1) (69). Moreover, the 10-amino artemisinins were equally active against the drug resistant strains (Table 1) with resistance indices (IC_{50} ratio between drug resistant and sensitive strains) of <3.5 for all compounds compared to >10 typically observed for CQ (Table 1) (70). Therefore, the 10-amino artemisinins show negligible cross-resistance potential against the Dd2, K1 and W2 genetic backgrounds (Table 1). The majority of compounds did not show overt cytotoxicity against HepG2 or CHO mammalian cell lines, with only ~10% inhibition of cell viability being observed even at 1000x the IC_{50} against asexual NF54 parasites for HepG2. EC_{50} values on CHO cells were on average higher than that of the reference drug, emetine (IC_{50} 340±90 nM). However, the 10-arylamine and 10-phenylurea derivatives may have potential toxicity issues as indicated by their EC_{50} values against CHO cells (2.9±1.4 and 2.4±1.0 µM respectively, Table 1).

Amino artemisinins display gametocytocidal activity. The inhibition of both early (>95% stage I-III) and late stage (~10% stage III and ~90% stage IV-V) gametocyte viability

was evaluated with *P. falciparum* NF54 luciferase reporter lines (71). Good intra-assay variability (Z-factors of 0.8) and acceptable inter-assay reproducibility (% CV of 14.5%) was observed. *In vitro* dose response analysis showed on average a two-fold improved activity for the 10-amino artemisinins against early stage gametocytes with IC_{50} values ranging from 1-83 nM in comparison to the reference compounds with IC_{50} values ranging between 37-95 nM (Table 2). Artemisone was the most potent 10-amino artemisinin, displaying activities against early stage gametocytes (IC_{50} = 1.94±0.11 nM) similar to those observed for asexual parasites (1.2±0.4 nM) (Table 2).

In vitro dose response analyses showed similar IC_{50} values for DHA against late stage gametocytes compared to early stage gametocytes (Table 2). However, a two- to four-fold increase in the IC_{50} was observed for artemisinin, artesunate and artemether against late stage gametocytes compared to the early stages (71). Decreased potency was also observed for the 10-sulfamide derivative that showed a preference for specificity towards early stage gametocytes.

Artemiside and the 10-arylamine and 10-phenylurea derivatives displayed incomplete kill curves after 48 h drug pressure against late stage gametocytes (Fig. S1), as previously observed for current clinical artemisinins (72). However, complete dose responsive kill curves were obtained after 72 h (73-75) drug pressure (Table 2), indicating a slow speed-of-action against these metabolically more latent stages (76). Under these conditions, artemiside and 10-phenylurea were the most potent compounds against late stage gametocytes (IC_{50} of 1.5 nM and 1.7 nM respectively, Table 2). The 10-arylamine derivative was slightly less potent (IC_{50} =16 nM). However, four of the 10-amino artemisinin derivatives (artemiside and the 10-sulfamide, 10-piperazine, and 10-phenylurea derivative) preferentially targeted late stage gametocytes,

ranging from two-fold late stage specificity for the 10-piperazine to 49-fold for the 10-phenylurea derivatives.

Previous reports indicate that artemisinins do not target mature stage V gametocytes (72). We therefore interrogated the effect of the 10-amino artemisinins showing late stage gametocyte specificity on late stage IV/V gametocytes (10% stage III, 50% stage IV, 40% stage V population) compared to their activity against enriched, mature stage V gametocytes (>95% stage V) with DHA as reference (Fig.3 and S2). As with DHA, artemisone, artemiside, and the 10-arylamine, 10-piperazine, and 10-phenylurea derivatives lost activity between stages IV to V gametocyte populations after 72 h drug exposure. However, the activities for artemisone, artemiside and the 10-phenylurea derivative against stage V gametocytes persisted at <250 nM (IC_{50} values of 126 nM, 209 nM, and 100 nM respectively Fig. S2), whereas a >10-fold loss in activity for DHA and compounds 10-arylamine and 10-piperazine was observed (IC_{50} values of 1287 nM, 1158 nM, and 800 nM respectively Fig. S2). We further evaluated the efficacy of these drugs an additional 24 h after drug washout. Under these conditions, the five 10-amino artemisinins tested were potently active against stage V gametocytes at concentrations below 100 nM, even though this was still significantly ($P<0.05$) higher than that observed against stage IV/V gametocytes (Fig.3). In all cases, the observed efficacies are due to the ability of the compounds to induce a death phenotype in the gametocytes, irrespective of the stage of gametocyte maturation. Dead/non-viable gametocytes were morphologically detected through Giemsa stained smears by a rounded appearance showing a punctate crystal formation indicative of unhealthy or dead gametocytes (Fig. 3) (73). Moreover, these stage V gametocytes were functionally compromised due to the inability of microgametocytes to exflagellate after 48 or 72 h of treatment with the 10-amino artemisinins (results not shown). Therefore, despite the

preference towards stage IV gametocytes and apparent slow kill kinetics, the five 10 amino-artemisinins tested show low nM activities against stage V gametocytes, making them at least twice as effective against stage V gametocytes as DHA.

Amino artemisinins show pan-reactivity towards asexual and sexual *P. falciparum* life cycle stages. Evaluation of the pan-reactivity - ability to target asexual parasites as well as early and late stage gametocytes - of the 10-amino artemisinins indicated that on average, a 13-fold loss in activity was seen between asexual and early stage gametocyte activities ($P = 0.0002$; Fig.4). Conversely, a 34-fold loss in activity was seen against late stage gametocytes ($P = 0.03$) (77, 78) compared to asexual parasites, with only a three-fold loss in activity associated between early and late stage gametocytes. However, even though a preference was observed towards asexual parasites, the compounds were still potent on both early and late stage gametocytes with IC_{50} values at <500 nM (Table 2), indicative of their ability to target multiple stages of intraerythrocytic *P. falciparum* parasites. The reference compounds all had a continuous decline in activity from the asexual parasites to early and late stage gametocytes, a trend generally observed for most antimalarial drugs (15, 78, 79). The 10-sulfamide derivative was the only 10-amino artemisinin showing a similar trend (Fig. 4). Although the 10-phenylurea derivative was equipotent with artemiside, there is a potential toxicity issue with the compound as noted above (Table 1). No other physicochemical properties including solubility and lipophilicity could be correlated to stage specific preference (data not shown).

Each of artemisone and artemiside with MB synergistically inhibits *P. falciparum* gametocytes. Fixed-ratio isobole analysis (80) was employed to evaluate the effect of combinations of the most potent oxidant drugs artemisone and artemiside with the redox drug MB (Fig. 5). Against asexual parasites, the combination of either artemisone or artemiside with

MB resulted only in additive interactions (mean ΣFIC of 1.14 and 1.02 against artemisone and artemiside, respectively). By contrast, the interactions of either artemisone or artemiside with MB were synergistic against both early and late stage gametocytes, as evident from concave isobolograms (Fig. 5) with mean ΣFIC values of 0.75 and 0.56 against early stage gametocytes and 0.61 and 0.73 against late stage gametocytes for artemisone and artemiside respectively. This synergism was confirmed with an independent isobole using the pLDH assay (Fig. 5), confirming the combined activity observed with the luciferase assay. The strongly synergistic interactions observed with the oxidant and redox drugs against both early and late stage gametocytes strongly supports the idea that redox-homeostasis regulated through several metabolic pathways is an essential mechanism for maintaining parasite viability in these stages in the parasite life cycle.

DISCUSSION

The development of a triple drug combination using an oxidant 10-amino artemisinin derivative with a redox drug and a third drug partner drug such as a 4(1*H*)-quinolone may provide a novel strategy in not only targeting erythrocytic stages of drug resistant malaria parasites but also the transmissible stages, effectively retarding the rate of resistance development and disease transmission. Here, we take the first step towards this aim and have established unambiguously the efficacy of lead 10-amino artemisinins in combination with a redox drug in effectively targeting various forms of malaria parasites in the erythrocytic stages.

Conversion of DHA into 10-amino artemisinins presents us with derivatives showing enhanced potency against drug sensitive asexual parasites, with preliminary data indicating that these compounds also maintain activity against C580Y mutant Cambodian field isolates (81)

(data to be presented elsewhere, personal communication, Dennis E. Kyle, University of Georgia, USA)(82). This provides at least a preliminary indication that these derivatives may not be as prone to the resistance exerted against the current clinical artemisinins, although eventual development of the resistance mechanisms such as K13-independent resistance phenotype cannot be excluded at this stage (4, 5). However, the fact that the 10-amino artemisinins not only inhibit asexual parasites, but also early and late sexual stage gametocytes within such a low nM range is most promising. In particular, the potency of artemisone and artemiside against both the asexual and sexual stages support the identification of these compounds as the lead pan-reactive oxidant compounds in this study.

A wide selection of assay platforms has shown that the peroxidic antimalarial drugs, including artemisone, have nM activities against late stage gametocytes (84-86). However, some recent reports seemingly contradict these observations (15, 72, 87). The detailed kinetic evaluation of the 10-amino artemisinins in the current study indicate that artemisone and artemiside are indeed potently active (IC_{50} 10-100 nM) against mature stage V gametocytes but notably have slower kill-kinetics against these forms of gametocytes. These activities correlate with the general ~ten-fold decrease in activity typically seen by other compounds as well (72, 78) between early to late stage gametocytes. Moreover, the potent activities of artemisone and artemiside against stage V gametocytes should translate into a substantial reduction of oocyst formation in a standard membrane feed assay, the results of which will be reported elsewhere. Moreover, future studies are required to show that these 10-amino artemisinins indeed translate to improved *in vivo* transmission-blocking, compared to the rather poor activity of DHA (72, 88).

The activities of the oxidant drugs artemisone and artemiside against gametocytes including mature stage V support recent reports wherein targeting redox metabolism

significantly affects these forms of the parasite (76). Mature stage V gametocytes are regarded as being metabolically hypoactive, due to their perceived inability to digest hemoglobin (89) and inability to respond to drug pressure on particular metabolic pathways (72). However, our data and that from Siciliano *et al.* (76) rather suggest that selective metabolic processes do remain active and are targetable in stage V gametocytes. In particular, the importance of antioxidant defense that is reliant on NADPH in transmissible gametocytes (76) coupled with our observation of the synergism between oxidant and redox reactive drugs strongly supports the need for a systematic investigation of redox maintenance and drug susceptibility in mature gametocytes. The maintenance of such potent activities of these artemisinins against late stage gametocytes tends to suggest that heme after all is not a prerequisite for activation of artemisinins.

It is of some note that artemisone and artemiside are active in rather different parasite environments. In asexual parasites and early stage gametocytes of *P. falciparum*, these artemisinins retain their ability to enhance oxidative stress. Such parasites as noted above have enhanced turnover of enzymes important for regulating redox-homeostasis in *P. falciparum.* Hemoglobin digestion and proper regulation of intracellular oxidative stress are essential in development of asexual and metabolically active early gametocyte stages (90). The additive effect observed with each of artemisone and artemiside with MB against asexual parasites correlates with a previous study performed with artemiside and MB (69). This can be attributed to an upregulation in redox-homeostasis in the asexual stages due to hemoglobin digestion, resulting in improved recovery from increased ROS production. Notably, such additive effects are maintained *in vivo* and are reflected in faster parasite clearance times for malaria patients treated with an oral artesunate-MB combination (91) and in two animal models infected with

different *Plasmodium* species treated with intravenous MB and artesunate (92). However, asexual parasites conferring CQ resistance have increased GSH production due to a fitness cost in hemoglobin digestion, and are therefore inherently more oxidatively stressed (93). This could explain why isobole analyses on asexual K1 parasites with artemether/artesunate and MB are synergistic (56).

For late stage gametocytes, the slower kill kinetics still reflect the same mode of action. The important issue is that in the absence of hemoglobin digestion for late stage gametocytes (37, 52), redox homeostasis is downregulated, making the parasite more sensitive to increased ROS production. Therefore, the combinations of each of artemisone and artemiside with MB results in synergism where the induction of oxidative stress by artemisone and artemiside is sustained or even enhanced by the redox cycling action of MB in gametocytes. These results are similar to those observed for plasmodione, a *P. falciparum* glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (*Pf*GluPho) inhibitor, and MB against stage V gametocytes (76). Overall, redox homeostasis is an exploitable target, especially for the intraerythrocytic gametocyte stages in the parasite life cycle.

In conclusion, this study demonstrates that the 10-amino artemisinin derivatives artemisone and artemiside have potent pan-reactive and potential transmission-blocking activity against the intraerythrocytic stages of *P. falciparum* parasites. Although the 10-sulfamide, 10-arylamine and the 10-piperazine derivatives are the most accessible of the amino artemisinins, the toxicity issue with the 10-arylamine aside, their further development is not warranted, based on the >10-fold loss in activity against late stage gametocytes. Although the 10-phenylurea is equipotent with artemiside, there is a potential toxicity issue with the compound as pointed out

above (Table 1), and accordingly, newer derivatives of the 10-phenylurea are being prepared and examined in all screens.

The low nM activities against asexual, early and late stage gametocytes, favorable resistance and selectivity indices and synergism with MB against gametocytes, of artemisone and artemiside makes these ideal candidate compounds for further development within combination therapies. Following the evolution of oxidant and redox drug combinations as described here, and the further examination of efficacies with selected lead 4(1*H*)-quinolones or other drugs with different mechanism of action is now warranted.

MATERIALS AND METHODS

Chemistry. The reference compounds used in this study as well as all tested compounds were ≥95% pure, unless otherwise indicated. Purity was determined using reverse-phase HPLC. Purities and instrumental conditions and additional data are presented in the Supplemental material. Artemisone was from an original sample batch prepared on pilot scale from DHA by activation with HCl-LiCl, and treatment of the intermediate β-chloride with thiomorpholine, and oxidation of the crude artemiside so obtained by hydrogen peroxide-acetonitrile, and recrystallized from ethyl acetate-hexane to provide needles, m.p. 152-153 °C (64, 65). Artemiside (needles, m.p. 152.5-153 °C), (64, 69) the 10-sulfamide derivative (needles, m.p. 168-169 °C) (64) and the 10-arylamino derivative (fine hair-like crystals, m.p. 170-171 °C) (63) were original samples prepared and purified by recrystallization. Analysis by hplc of the 10-sulfamide under reverse phase conditions indicates a purity of 93%.

10α-(Piperazin-1'-yl)-10-deoxo-10-dihydroartemisinin 10-piperazine was prepared as follows. A solution of dihydroartemisinin (5.05 g, 17.6 mmol) in dichloromethane (25 mL) at room temperature was treated with oxalyl chloride (1.7 mL, 19.4 mmol, 1.1 equiv.) and stirred for 30 min under nitrogen. After 30 min, the reaction mixture was transferred via cannula into a flask containing a solution of anhydrous piperazine (4.55 g, 52.8 mmol, 3 equiv.) in dichloromethane (50 mL), and stirred for 3 hours at room temperature under nitrogen. The reaction mixture was then diluted with dichloromethane (100 mL). It was washed with deionized water (3 x 30 mL) followed with brine (2 x 30 mL), dried over $MgSO_4$ and then filtered. The filtrate was concentrated by evaporation under reduced pressure. The residue was purified by flash column chromatography over silica gel with dichloromethane-methanol-triethylamine (10:1:0.1) to obtain the highly polar product as a white solid (4.96 g, 80%). Whilst recrystallization from diethyl ether or diethyl ether-ethyl acetate gave the 10-piperazine compound as fine needles, m.p. 163-164 °C, the compound was best used as the fraction isolated directly by chromatography followed by drying under high vacuum. ^{1}H NMR (600 MHz, $CDCl_3$) δ (ppm) 0.74 (d, *J* = 7.3 Hz, 3H, H-14), 0.91 (d, *J* = 6.3 Hz, 3H, H-15), 1.36 (s, 3H, H-13), 1.62 - 1.69 (m, 2H, H-7), 2.29 (td, *J* = 14.0, 3.9 Hz, 1H, H-4), 2.48-2.53 (m, 1H, H-8a), 2.93-3.01 (m, 2H, H-2',H-6'), 3.13-3.23 (m, 6H, H-2', H-3', H-4', H-5'), 4.0 (d, *J* = 10.2 Hz, 1H, H-10), 5.24 (s, 1H, H-12); ^{13}C NMR (151 MHz, $CDCl_3$) δ (ppm): 103.96 (C-3), 91.64 (C-10), 91.06 (C-12), 80.34 (C-12a), 51.74 (C-5a), 50.70 (C-2', C-6'), 45.84 - 45.69 (C-3', C-5'), 26.02 (C-13), 24.78 (C-5), 21.67 (C-7), 20.31 (C-15), 13.45 (C-14); IR ν_{max} cm^{-1}: 3261, 2926, 2869, 2839, 1738, 1453, 1408, 1375, 1349. MS (ESI) *m/z* calcd. for $C_{19}H_{32}N_2O_4$+H 353.2440; found 353.2469 $[M+H]^+$. It was not possible to assess purity of the compound under the reverse phase condition used for the other aminoartemisinins, evidently due to decomposition. However, as

gauged by its crystallinity and melting point, and its clean conversion into the 10-phenylurea, the compound was suitable for assessment of its biological activities.

10α-[4'-(Phenylaminocarbonyl)piperazin-1'-yl]-10-deoxo-10-dihydroartemisinin 10-phenylurea was prepared as follows. A solution of phenyl isocyanate (0.11 mL, 1 mmol, 1 equiv.) and the 10-piperazine derivative (352 mg) in dichloromethane (5 mL) was stirred for 24 h. The mixture was then concentrated directly by evaporation under reduced pressure. Analysis of the residue by ^{1}H NMR spectroscopy indicated essentially quantitative conversion of 10-piperazine derivative into the 10-phenylurea. The latter was isolated by chromatography of the residue over silica gel with ethyl acetate-hexane 40:60, evaporation of the eluate and crystallization from ethyl acetate-hexane to give the 10-phenylurea as white plates (287 mg, 60%), m.p. 162-163 °C, $[\alpha]_D^{20}$ +12.41 (*c* = 0.58, $CHCl_3$). ^{1}H NMR spectrum (400 MHz) δ 0.83 (d, *J* = 7.2Hz, 3 H, 6-Me), 0.95 (d, *J* = 6 Hz, 3 H, 9-Me), 0.96-1.06 (m, 1 H), 1.38 (s, 3 H, 3-Me), 1.20-1.34 (m, 3 H), 1.45-1.49 (m, 1 H), 1.53-1.58 (m, 1 H), 1.69-1.74 (m, 2 H), 1.84-1.88 (m, 1 H), 1.97-2.03 (m, 1 H), 2.31-2.39 (m, 1 H), 2.57-2.63 (m, 1 H), 2.69-3.06 (m, 4 H, piperazine), 3.47-3.48 (m, 4 H, piperazine), 4.06 (d, *J* = 10 Hz, 1 H, H-10), 5.28 (s, 1 H, H-12), 6.40 (s, 1 H, NH), 7.02 (t, *J* = 7.2 Hz, 1 H, ArH), 7.25-7.29 (m, 2 H, ArH), 7.34-7.36 (m, 2 H, ArH); ^{13}C NMR δ = 13.48, 20.78, 21.63, 24.74, 25.99, 28.48, 34.26, 36.29, 37.39, 44.44, 45.79, 47.14, 51.69, 80.30, 90.65, 91.61, 103.97, 119.91, 122.95, 128.83, 139.08, 154.99; IR (KBr): ν_{max} = 500, 552, 694, 757, 880, 925, 984, 1022, 1041, 1061, 1113, 1134, 1160, 1186, 1207, 1240, 1316, 1351, 1380, 1399, 1445, 1501, 1527, 1599, 1661, 2849, 2868, 2922, 2954, 3415 cm^{-1}, MS (ESI): *m/z* = calcd for $C_{26}H_{37}N_3O_5$ + H: 472.2811, found: 472.2806 [M^++H].

Efficacy Studies

***In vitro* maintenance of asexual parasites and gametocyte production.** *In vitro P. falciparum* parasites (NF54, K1 and W2) were cultured in human O^+ erythrocytes under 90% N_2, 5% CO_2 and 5% O_2 atmospheric conditions with supplemented RPMI 1640 media containing Albumax I, as previously described (94). Synchronized, ring stage parasites (>95%) were obtained using a 5% D-sorbitol (Sigma-Aldrich) treatment (94). Parasite proliferation was monitored microscopically using Giemsa stained smears. Gametocytogenesis was induced and maintained as previously described (71) through a combination of glucose depletion and a decrease in hematocrit from a >95% synchronized, ring stage asexual population (~10% parasitemia). Gametocyte cultures were kept stationary under 90% N_2, 5% CO_2 and 5% O_2 atmospheric conditions at 37°C and treated with 50 mM *N*-acetyl-glucosamine (NAG, Sigma-Aldrich) to eliminate residual invasion of asexual parasites.

***In vitro* antimalarial assays against asexual *P. falciparum* parasites.** Artemisinin, DHA, artesunate, artemether, the 4-aminoquinoline chloroquine (CQ) and MB were used as reference drugs for asexual stage parasite assays. Compound working solutions were prepared from a 10 mM stock solution in 100% (v/v) DMSO (Sigma-Aldrich) in supplemented RPMI 1640 media containing Albumax I with a final DMSO concentration of <0.1% (v/v), previously determined as non-toxic to intraerythrocytic asexual parasites and gametocytes. Dose response of the 10-amino artemisinins were assayed using a two-fold serial drug dilution on *in vitro* >95% ring stage intraerythrocytic *P. falciparum* parasites at 37°C under 90% N_2, 5% CO_2 and 5% O_2 atmospheric conditions, detecting either parasite lactate dehydrogenase (pLDH) absorbance (95) as metabolic indicator following a 48 h drug treatment (1.5-2% parasitemia and 2% hematocrit) or SYBR Green I fluorescence as proliferative marker following a 96 h drug treatment (1% parasitemia and 1% hematocrit) (94, 96). No drug washout steps were performed during drug

incubation periods prior to assays. Activity against *P. falciparum* drug sensitive NF54 and resistant Dd2 (CQ, pyrimethamine, mefloquine and cycloguanil), K1 (CQ, quinine, pyrimethamine and cycloguanil) and W2 (CQ, quinine, pyrimethamine and CYC) strains were evaluated. Data analysis was performed using GraphPad Prism 6 and intra-assay variability was monitored with Z-factors and acceptable inter-assay reproducibility with % CV (71). Data per compound are from at least three independent biological replicates, each performed in technical triplicates and results expressed as the compound concentration at which 50% parasite viability/proliferation is affected (IC_{50}).

***In vitro* cytotoxicity determination against mammalian cells.** Caucasian hepatocellular carcinoma cells (HepG2) were maintained as previously described (94), and the cytotoxicity (at 1000x-fold the IC_{50} value against asexual *P. falciparum* parasites) determined using a lactate dehydrogenase assay (LDH) viability assay (BioVision Inc.). Cytotoxicity (EC_{50}) was also determined against the Chinese hamster ovary mammalian cells (CHO) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay (97, 98) with emetine as reference drug. Assays were performed for a single biological repeat in technical triplicates.

***In vitro P. falciparum* gametocytocidal assays.** Excluding CQ, the same reference compounds used against asexual *P. falciparum* parasites, were used for intraerythrocytic early and late gametocyte stage assays. Gametocytocidal activity was determined using luciferase reporter lines (57, 71) to derive dose responses with two-fold serial drug dilutions for 48 h against early stage gametocytes (day 5 post induction population, ~95% stage I-III) and ten-fold serial drug dilutions for 48 h and 72 h against late stage gametocytes (day 10 post induction population, ~90% late stage IV/V) (2-3% gametocytemia, 2% hematocrit), at 37°C under 90% N_2, 5% CO_2 and 5% O_2 atmospheric conditions. No drug washout steps were performed during

drug incubation periods prior to assays. In all cases, an interference assay was run in parallel to eliminate false positives if possible compound interference with luciferase readout existed. Data per compound are from at least three independent biological replicates, unless otherwise indicated, each performed in technical triplicates and results expressed as the compound concentration at which 50% parasite viability is affected (IC_{50}).

Gametocytocidal stage-specific and kill kinetic evaluation of compounds against late stage gametocytes. Late stage gametocytes, stage IV/V (10% stage III, 50% stage IV, 40% stage V population on day 10 post induction) or mature stage V (>95% stage V on day 13 post induction) were used to determine the differential stage specificity and kill kinetics (speed-of-action) of DHA, artemisone, artemiside, the 10-arylamine, 10-piperazine, and the 10-phenylurea derivatives between stage IV and V gametocytes. Dose responses were determined using a luciferase reporter line, exposed to ten-fold serial drug dilutions for 72 h at 37°C under 90% N_2, 5% CO_2 and 5% O_2 atmospheric conditions. Treatment for shorter periods (e.g. 24 h) did not result in accurate dose response determination of any compound, irrespective of gametocyte population used, confirming the insensitivity of gametocytes to short periods of perturbation (99). Additionally, a drug washout step was included, by replacing drug containing spent medium with fresh medium (without drug) followed by a further 24 h incubation prior to measuring luciferase activity. In addition, gametocyte viability was monitored morphologically and by detection of exflagellation events at the initiation and completion of the experiment with a 20 min exposure to 1 mM xanthurenic acid (XA, Sigma Aldrich) at room temperature. Population compositions were determined microscopically using Giemsa stained smears before (0 h) and after (72 h/72+24 h) incubations for both treated and untreated populations at 2x IC_{50}. Data are the means from a single independent biological experiment with technical triplicates,

and results expressed as the compound concentration at which 50% parasite viability is affected (IC_{50}). * = P<0.05; ** = P<0.01; *** = P<0.001, unpaired t-test.

Combination of artemisone/artemiside with MB. The *in vitro* interactions of artemisone and artemiside with MB was determined using a fixed-ratio isobole analysis (80) for NF54 asexual parasites (SYBR Green I-based fluorescence) and early and late stage gametocytes (luciferase reporter lines). Shortly, the drugs were applied alone and in fixed-drug combination ratios (artemisone/artemiside:MB) of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 and serially diluted (two-fold for asexual parasites with 96 h incubations and early stage gametocytes (48 h incubations) and ten-fold for late stage gametocytes with 72 h incubations) to obtain the IC_{50} dose response curves for each drug alone and in the fixed-drug ratio. To confirm drug interactions observed on late stage gametocytes, isobole analysis for artemisone and MB only also was performed using the pLDH assay (73). Four fixed doses of MB (25.00, 6.25, 1.56, 0.39, 0 nM) were added to dose-response curves of artemisone (from the dose of 100 nM to 0.8nM).

In addition, an independent dose response curve of MB is performed to obtain the IC_{50} of MB. The fractional inhibitory concentration (FIC) for each drug in the combination was calculated as follows:

$$\text{FIC (artemisone/artemiside)} = \frac{IC_{50} \text{ of artemisone/artemiside in combination with MB}}{IC_{50} \text{ (artemisone/artemiside)}}$$

The paired FIC values for the drugs in each combination were linearly plotted producing an isobologram. The ΣFIC of FIC (artemisone/artemiside) in combination with FIC (MB) was determined by calculating the mean FIC value, to obtain the representative FIC value for the drug combination. A mean ΣFIC <1.0 represents a synergistic interaction, >1.3 an antagonistic

interaction where ΣFIC=1 an indifferent/additive interaction (100). These assay platforms correlate well for the gametocyte stages as they both measure viability. Data per isobologram using the SYBR Green I fluorescence, luciferase reporter line and data for the artemisone and MB isobologram using the pLDH assay are from at least three independent biological replicates, each performed in technical triplicates.

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL FILE 1, PDF file, 1.56 MB ^{1}H and mass spectra are given for the amino artemisinins, and purities as assessed by hplc analyses are given in Part 1. In Part 2 as associated with efficacy studies are given Fig. S1 and Fig. S2 with Figure legends.

ACKNOWLEDGMENTS

The authors would like to acknowledge the assistance of Carmen de Kock and Daniel J. Watson from the Division of Pharmacology, Department of Medicine, Groote Schuur Hospital, University of Cape Town and Lung Chung Man, Yuet Wu and Kwan Wing Cheu from the Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong.

Funding Sources This work was funded by the South African Medical Research Council (MRC) Flagship Project MALTB-Redox with funds from National Treasury under its Economic Competitiveness and Support Package to Richard K. Haynes, the South African MRC Strategic Health Innovation Partnership (SHIP) grant, a South African MRC Collaborative Centre for Malaria Research grant and a South African National Research Foundation grant (UID 84627) to

Lyn-Marie Birkholtz and South African National Research Foundation Grants to Richard K. Haynes (UIDs 90682 and 98934). Donatella Taramelli and Sarah D'Alessandro acknowledge the support from the Global Health Program of the Bill & Melinda Gates Foundation. (Grant OPP1040394 to D.T., Pietro Alano Coordinator and the COST Action CM1307).

Disclaimer. Any opinions, findings and conclusions, or recommendations expressed in this material are those of the authors and therefore the NRF does not accept any liability in regard thereto.

ABBREVIATIONS

ACT, artemisinin combination therapy; CHO, Chinese hamster ovary mammalian cells; CQ, chloroquine; FIC, fractional inhibitory concentration; G6PD, glucose-6-phosphate dehydrogenase; GR, glutathione reductase; GSSG, oxidized glutathione; HepG2, Caucasian hepatocellular carcinoma cells; MB, Methylene Blue; *P. falciparum*, *Plasmodium falciparum*; *Pf*K13, *P. falciparum* Kelch13; *P. falciparum* phosphatidylinositosol-3-kinase, *Pf*PI3K; *Pf*GluPho, *P. falciparum* glucose-6-phosphate dehydrogenase-6-phoshopgluconolactonase; phosphatidylinositosol-3-phosphate, PI3P; RI, resistance index; SI, selectivity index; TrxR, thioredoxin reductase.

REFERENCES

1. WHO. 2016. WHO world malaria report 2016. World Health Organisation, Geneva, Switzerland.
2. Lubell Y, Dondorp A, Guérin PJ, Drake T, Meek S, Ashley E, Day NP, White NJ, White LJ. 2014. Artemisinin resistance – modelling the potential human and economic costs. Malar J 13:452.

3. Paloque L, Ramadani AP, Mercerea-Puijalon O, Augereau JM, Benoit-Vical F. 2016. *Plasmodium falciparum*: multifaceted resistance to artemisinins. Malar J 15:149.
4. Sutherland CJ, Lansdell P, Sanders M, Muwanguzi J, van Schalkwyk DA, Kaur H, Nolder D, Tucker J, Bennett HM, Otto TD, Berriman M, Patel TA, Lynn R, Gkrania-Klotsas E, Chiodini PL. 2017. *Pf*k13-independent treatment failure in four imported cases of *Plasmodium falciparum* malaria treated with artemether-lumefantrine in the United Kingdom. Antimicrob Agents and Chemother 61:e02382-16.
5. Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, Zhu G, Tang J, Liu Y, Wang W, Cao Y, Xu S, Gu Y, Li J, Zhang C, Gao Q, Menard D, Pain A, Yang H, Zhang Q, Cao J. 2017. Emergence of indigenous artemisinin-resistant *Plasmodium falciparum* in Africa. N Engl J Med 376:991-993.
6. Price RN. 2013. Potential of artemisinin-based combination therapies to block malaria transmission. J Infect Dis 207:1627-1629.
7. Dama S, Niangaly H, Ouattara A, Sagara I, Sissoko S, Traore OB, Bamadio A, Dara N, Djimde M, Alhousseini ML, Goita S, Maiga H, Dara A, Doumbo OK, Djimde AA. 2017. Reduced ex vivo susceptibility of *Plasmodium falciparum* after oral artemether–lumefantrine treatment in Mali. Malar J 15:59.
8. Roberto A, Pharath L, Olivo M, Chanaki A, Dalin D, Richard DP, Jacob A, Aaron TN, Sokunthea S, Seila S, Eleanor D, Dushyant J, Jim S, Dominic PK, Fairhurst RM. 2016. Genetic markers associated with dihydroartemisinin–piperaquine failure in *Plasmodium falciparum* malaria in Cambodia: a genotype–phenotype association study. Lancet Infect Dis 17:164-173.
9. Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, Kim S, Witkowski B, Duru V, Domergue A, Khim N, Ringwald P, Menard D. 2015. Evidence of *Plasmodium falciparum* malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother 59:4719-4726.

10. Pascual A, Madamet M, Briolant S, Gaillard T, Amalvict R, Benoit N, Travers D, Pradines B. 2015. French national reference centre for imported malaria study group. Multinormal *in vitro* distribution of *Plasmodium falciparum* susceptibility to piperaquine and pyronaridine. Malar J 14:49.

11. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ. 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on *Plasmodium falciparum* polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Diseases 210:344-353.

12. Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, Quang HH, Farrar J, Thwaites G, White NJ, Wolbers M, Hien TT. 2017. Rapid decline in the susceptibility of *Plasmodium falciparum* to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J 16:27.

13. Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, Mazzuri S, Möhrle JJ, Wells TNC. 2017. New developments in anti-malarial target candidate and product profiles. Malar J 16:26.

14. WWARN. 2016. Gametocyte study research group. Gametocyte carriage in uncomplicated *Plasmodium falciparum* malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Medicine 14:79.

15. Peatey CL, Leroy D, Gardiner DL, Trenholme KR. 2012. Anti-malarial drugs: how effective are they against *Plasmodium falciparum* gametocytes? Malar J 11:34.

16. Haynes RK, Chan WC, Wong HN, Li KY, Wu W, Fan K, Sung HY, Williams ID, Prosperi D, Melato S, Coghi P, Monti D. 2010. Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: relationship with flavoenzyme function and antimalarial mechanism of action. Chem Med Chem 5:1282-1299.

17. Haynes RK, Cheu KW, Chan HW, Wong HN, Li KY, Tang MM, Chen MJ, Guo ZF, Guo ZH, Sinniah K, Witte AB, Coghi P, Monti D. 2012. Interactions between artemisinins and other

antimalarial drugs in relation to the cofactor mode-a unifying proposal for drug action. Chem Med Chem 7:2204-2226.

18. Haynes RK, Cheu K-W, N'Da DD, Coghi P, Monti D. 2013. Considerations on the mechanism of action of artemisinin antimalarials: part 1 - The 'carbon radical' and 'heme' hypotheses. Infectious Disorders – Drug Targets 13:217-277.

19. Müller T, Johann L, Jannack B, Brückner M, Lanfranchi DA, Bauer H, Sanchez C, Yardley V, Deregnaucourt D, Schrével J, Lanzer M, Schirmer RH, Davioud-Charvet E. 2011. Glutathione reductase-catalyzed cascade of redox reactions to bioactivate potent antimalarial 1,4-naphthoquinones - a new strategy to combat malarial parasites. J Am Chem Soc 133:11557–11571.

20. Mohring F, Pretzel J, Jortzik E, Becker K. 2014. The redox systems of *Plasmodium falciparum* and *Plasmodium vivax*: comparison, in silico analyses and inhibitor studies. Curr Med Chem 21:1728-1756.

21. Rathore S, Datta G, Kaur I, Malhotra P, Mohmmed A. 2015. Disruption of cellular homeostasis induces organelle stress and triggers apoptosis like cell-death pathways in malaria parasite. Cell Death Dis 6:e1803.

22. Beteck RM, Coertzen D, Smit FJ, Birkholtz L-M, Haynes RK, N'Da DD. 2016. Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. Bioorg Med Chem Lett 26:3006-3009.

23. Andriole VT. 2005. The quinolones – past, present and future. Clin Infec Dis 41:S113.

24. Beteck RM, Smit FJ, Haynes RK, N'Da DD. 2014. Recent progress in the development of anti-malarial quinolones. Malar J 13:339.

25. Monastyrskyi A, Kyle DE, Manetsch R. 2014. 4(1H)-Pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities. Curr Top Med Chem 14:1693-1705.

26. Stickles AM, Smilkstein MJ, Morrisey JM, Li Y, Forquer IP, Kelly JX, Pou S, Winter RW, Nilsen A, Vaidya AB, Riscoe MK. 2016. Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria. Antimicrob Agents Chemother 60:4853-4859.

27. O'Neill PM, Posner GH. 2004. A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 47:2945-2964.

28. Klonis N, Creek DJ, Tilley L. 2013. Iron and heme metabolism in *Plasmodium falciparum* and the mechanism of action of artemisinins. Curr Opin Microbiol 16:722-7.

29. Wang J, Xu C, Lun ZR, Meshnick SR. 2017. Unpacking 'Artemisinin Resistance'. Trends Pharmacol Sci 38:506-511.

30. Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, He Y, Yuan LX, Lim TK, Liu M, Liew CX, Lee YQ, Zhang J, Lu N, Lim CT, Hua ZC, Liu B, Shen HM, Tan KS, Lin Q. 2015. Haem-activated promiscuous targeting of artemisinin in *Plasmodium falciparum*. Nat Commun 6:10111.

31. Ismail HM, Barton V, Phanchana M, Charoensutthivarakul S, Wong MH, Hemingway J, Biagini GA, O'Neill PM, Ward SA. 2016. Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites *Plasmodium falciparum* 3D7. Proc Natl Acad Sci U S A 113:2080-2085.

32. Ismail HM, Barton VE, Panchana M, Charoensutthivarakul S, Biagini GA, Ward SA, O'Neill PM. 2016. A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile. Angew Chem Int Ed Engl 55:6401-6405.

33. Krauth-Siegel RL, Bauer H, Schirmer RH. 2005. Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Internat Ed 44:690–715.

34. Goyal M, Alam A, Bandyopadhyay U. 2012. Redox regulation in malaria: current concepts and pharmacotherapeutic implications. Curr Med Chem 19:1475-1503.

35. Atamna H, Pascarmona G, Ginsburg H. 1994. Hexose monophosphate shunt activity in intact *Plasmodium falciparum*-infected erythrocytes and in free parasites. Mol Biochem Parasitol 67:79-89.

36. Becker K, Rahlfs S, Nickel C, Schirmer RH. 2003. Glutathione-functions and metabolism in the malarial parasite *Plasmodium falciparum*. Biol Chem 384:551–566.

37. Müller S. 2004. Redox and antioxidant systems of the malaria parasite *Plasmodium falciparum*. Molecular Microbiol 53:1291-1305.

38. Kinoshita A, Nakayama Y, Kitayama T, Tomita M. 2007. Simulation study of methemoglobin reduction in erythrocytes. Differential contribution of two pathways to tolerance to oxidative stress. FEBS J 274:1449-1458.

39. Schirmer RH, Müller JG, Krauth- Siegel RL. 1995. Disulfide-reductase inhibitors as chemotherapeutic agents: the design of drugs for trypanosomiasis and malaria. Angew Chem Internat Ed 34:141-154.

40. Parapini S, Basilico N, Mondani M, Olliaro P, Taramelli D, Monti D. 2004. Evidence that haem iron in the malaria parasite is not needed for the antimalarial effects of artemisinin. FEBS Lett 575:91-94.

41. Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ, Tilley L. 2011. Artemisinin activity against *Plasmodium falciparum* requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A 108:11405-11410.

42. Antoine T, Fisher N, Amewu R, O'Neill PM, Ward SA, Biagini GA. 2014. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J Antimicrob Chemother 69:1005-1016.

43. Gopalakrishnan AM, Kumar N. 2015. Antimalarial action of artesunate involves DNA damage mediated by reactive oxygen species. Antimicrob Agents Chemother 59:317-325.

44. Van Hook AM. 2015. Antimalarial drugs inhibit PI3P production. Sci Signal 8:ec118.

45. Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Njimoh DL, Ryan Y, Chotivanich K, Nguon C, Ghorbal M, Lopez-Rubio J, Pfrender M, Emrich S, Mohandas N, Dondorp AM, Wiest O, Haldar K. 2015. A molecular mechanism of artemisinin resistance in *Plasmodium falciparum* malaria. Nature 520:683-687.

46. Okoh VO, Felty Q, Parkash J, Poppiti R, Roy D. 2013. Reactive oxygen species via redox signaling to PI3K/AKT pathway contribute to the malignant growth of 4-hydroxy estradiol-transformed mammary epithelial cells. PLoS ONE 8:e54206.

47. Liu J, Zhou J, Xing D. 2012. Phosphatidylinositol 3-kinase plays a vital role in regulation of rice seed vigor via altering NADPH oxidase activity. PLoS ONE 7:e33817.

48. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. 2005. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 105:1717-1723.

49. Schirmer RH, Coulibaly B, Stich A, Scheiwein M, Merkle H, Eubel J, Becker K, Becher H, Müller O, Zich T, Schiek W, Kouyate B. 2003. Methylene blue as an antimalarial agent. Redox Rep 8:272-276.

50. Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S. 2008. Interactions of methylene blue with human disulfide reductases and their orthologues from *Plasmodium falciparum*. Antimicrob Agents Chemother 52:183-191.

51. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. 1995. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother 39:2671-2677.

52. Sarma GN, Savvides SN, Becker K, Schirmer M, Schirmer RH, Karplus PA. 2003. Glutathione reductase of the malarial parasite *Plasmodium falciparum*: Crystal structure and inhibitor development. J Mol Biol 328:893-907.

53. Haynes RK, Cheu KW, Tang MM, Chen MJ, Guo ZF, Guo ZH, Coghi P, Monti D. 2011. Reactions of antimalarial peroxides with each of leucomethylene blue and dihydroflavins: flavin reductase and the cofactor model exemplified. Chem Med Chem 6:279-291.

54. Rengelshausen J, Burhenne J, Fröhlich M, Tayrouz Y, Singh SK, Riedel K-D, Müller O, Hoppe-Tichy T, Haefeli WE, Mikus G, Walter-Sack I. 2004. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol 60:709-715.

55. Pascual A, Henry M, Briolant S, Charras S, Baret E, Amalvict R, des Etages EH, Feraud M, Rogier C, Pradines B. 2011. *In vitro* activity of Proveblue (methylene blue) on *Plasmodium falciparum* strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother 55:2472 –2474.

56. Akoachere M, Buchholz K, Fischer E, Burhenne J, Haefeli WE, Schirmer RH, Becker K. 2005. *In vitro* assessment of methylene blue on chloroquine-sensitive and -resistant *Plasmodium falciparum* strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother 49:4592–4597.

57. Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH, Eappen AG, Richman A, Sim BK, Lee MC, Hoffman SL, Fidock DA. 2011. Quantitative assessment of *Plasmodium falciparum* sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A 108:1214-1223.

58. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P. 2000. Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet 39:255-270.

59. Wesche DL, DeCoster MA, Tortella FC, Brewer TG. 1994. Neurotoxicity of artemisinin analogs *in vitro*. Antimicrob Agents Chemother 38:1813-1819.

60. Genovese RF, Newman DB. 2008. Understanding artemisinin-induced brainstem neurotoxicity. Arch Toxicol 82:379-385.

61. Ramos-Martin V, Gonzalez-Martinez C, Mackenzie I, Schmutzhard J, Pace C, Lalloo DG, Terlouw DJ. 2014. Neuroauditory toxicity of artemisinin combination therapies-have safety concerns been addressed? Am J Trop Med Hyg 91:62-73.

62. Haynes RK, Chan HW, Lung CM, Ng NC, Wong HN, Shek LY, Williams ID, Gomes MF, Cartwright A. 2007. Artesunate and dihydroartemisinin (DHA): unusual decomposition products

formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. Chem MedChem 2:1448-1463.

63. Haynes RK, Chan HW, Ho WY, Ko CK, Gerena L, Kyle DE, Peters W, Robinson BL. 2005. Convenient access both to highly antimalaria-active 10-arylaminoartemisinins, and to 10-alkyl ethers including artemether, arteether, and artelinate. Chembiochem 6:659-667.

64. Haynes RK, Fugmann B, Stetter J, Rieckmann K, Heilmann HD, Chan HW, Cheung MK, Lam WL, Wong HN, Croft SL, Vivas L, Rattray L, Stewart L, Peters W, Robinson BL, Edstein MD, Kotecka B, Kyle DE, Beckermann B, Gerisch M, Radtke M, Schmuck G, Steinke W, Wollborn U, Schmeer K, Romer A. 2006. Artemisone-a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed Engl 45:2082-2088.

65. Haynes RK. 2008. Strategies in the development and chemical modification of the new artemisinin antimalarial artemisone. Synform 3:34-36.

66. Haynes RK, Wong HN, Wu Y, Wu WK, Cheu KW, Williams ID, Krishna S, Slavic K, Gravett AM, Liu WM. 2016. Methylene homologues of artemisone: an unexpected structure–activity relationship and a possible implication for the design of C10-substituted artemisinins. ChemMedChem 11:1469-1479.

67. Schmuck G, Temerowski M, Haynes RK, Fugmann B. 2003. Identification of non-neurotoxic artemisinin derivatives in vivo and in vitro., p 35-47, Res Adv in Antimicrob Agents and Chemother.

68. Haynes RK, Ho W-Y, Chan H-W, Fugmann B, Stetter J, Croft SL, Vivas L, Peters W, Robinson BL. 2004. Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew Chem Int Ed 43:1381 –1385.

69. Guo J, Guiguemde AW, Bentura-Marciano A, Clark J, Haynes RK, Chan WC, Wong HN, Hunt NH, Guy RK, Golenser J. 2012. Synthesis of artemiside and its effects in combination with conventional drugs against severe murine malaria. Antimicrob Agents Chemother 56:163-73.

70. Nzila A, Mwai L. 2010. *In vitro* selection of *Plasmodium falciparum* drug-resistant parasite lines. J Antimicrob Chemother 65:390-398.

71. Reader J, Botha M, Theron A, Lauterbach SB, Rossouw C, Engelbrecht D, Wepener M, Smit A, Leroy D, Mancama D, Coetzer LC, Birkholtz L. 2015. Nowhere to hide: interrogating different metabolic parameters of *Plasmodium falciparum* gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. Malar J 14:213.

72. Plouffe DM, Wree M, Du AY, Meister S, Li F, Patra K, Lubar A, Okitsu SL, Flannery EL, Kato N, Tanaseichuk O, Comer E, Zhou B, Kuhen K, Zhou Y, Leroy D, Schreiber SL, Scherer CA, Vinetz J, Winzeler EA. 2016. High-throughput assay and discovery of small molecules that interrupt malaria transmission. Cell Host Microbe 19:114-126.

73. D'Alessandro S, Silvestrini F, Dechering K, Corbett Y, Parapini S, Timmerman M, Galastri L, Basilico N, Sauerwein R, Alano P, Taramelli D. 2013. A *Plasmodium falciparum* screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection. J Antimicrob Chemother 68:2048-58.

74. Bolscher JM, Koolen KM, van Gemert GJ, van de Vegte-Bolmer MG, Bousema T, Leroy D, Sauerwein RW, Dechering KJ. 2015. A combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct dynamics of marketed and experimental drugs. J Antimicrob Chemother 70:1357-66.

75. Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC, Williamson KC, Zheng W. 2014. Chemical signatures and new drug targets for gametocytocidal drug development. Sci Rep 4:3743.

76. Siciliano G, Santha Kumar TR, Bona R, Camarda G, Calabretta MM, Cevenini L, Davioud-Charvet E, Becker K, Cara A, Fidock DA, Alano P. 2017. A high susceptibility to redox imbalance of the transmissible stages of *Plasmodium falciparum* revealed with a luciferase-based mature gametocyte assay. Mol Microbiol 104:306-331.

77. Almela MJ, Lozano S, Lelievre J, Colmenarejo G, Coteron JM, Rodrigues J, Gonzalez C, Herreros E. 2015. A new set of chemical starting points with *Plasmodium falciparum* transmission-blocking potential for antimalarial drug discovery. PLoS ONE 10:e0135139.

78. Duffy S, Avery VM. 2013. Identification of inhibitors of *Plasmodium falciparum* gametocyte development. Malar J 12:408.

79. Lucantoni L, Avery V. 2012. Whole-cell *in vitro* screening for gametocytocidal compounds. Future Med Chem 4:2337-2360.

80. Fivelman QL, Adagu IS, Warhurst DC. 2004. Modified Fixed-Ratio Isobologram Method for Studying In Vitro Interactions between Atovaquone and Proguanil or Dihydroartemisinin against Drug-Resistant Strains of *Plasmodium falciparum*. Antimicrob Agents Chemother 48:4097-4102.

81. Hott A, Casandra D, Sparks KN, Morton LC, Castanares GG, Rutter A, Kyle DE. 2015. Artemisinin-resistant *Plasmodium falciparum* parasites exhibit altered patterns of development in infected erythrocytes. Antimicrob; Agents Chemother; 59:3156-3167.

82. Lanteri CA, Chaorattanakawee S, Lon C, Saunders DL, Rutvisuttinunt W, Yingyuen K, Bathurst I, Ding XC, Tyner SD. 2014. *Ex vivo* activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant *Plasmodium falciparum* isolates from Cambodia. Antimicrob Agents Chemother 58:5831-5840.

83. Ariey F, Witkowski B, Amarantunga C, Beghain J, Langlois KKA, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chour CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin resistant *Plasmodium falciparum* malaria. Nature 51:50-55.

84. D'Alessandro S, Camarda G, Corbett Y, Siciliano G, Parapini S, Cevenini L, Michelini E, Roda A, Leroy D, Taramelli D, Alano P. 2016. A chemical susceptibility profile of the *Plasmodium falciparum* transmission stages by complementary cell-based gametocyte assays. J Antimicrob Chemother 71:1148-1158.

85. Lucantoni L, Duffy S, Adjalley SH, Fidock DA, Avery VM. 2013. Identification of MMV malaria box inhibitors of *Plasmodium falciparum* early-stage gametocytes using a luciferase-based high-throughput assay. Antimicrob Agents Chemother 57:6050-6062.

86. Lucantoni L, Fidock DA, Avery VM. 2016. Luciferase-based, high-throughput assay for screening and profiling transmission-blocking compounds against *Plasmodium falciparum* gametocytes. Antimicrob Agents Chemother 60:2097-2107.

87. Lelievre J, Almela MJ, Lozano S, Miguel C, Franco V, Leroy D, Herreros E. 2012. Activity of clinically relevant antimalarial drugs on *Plasmodium falciparum* mature gametocytes in an ATP bioluminescence "transmission blocking" assay. PLoS ONE 7:e35019.

88. Vos MW, Stone WJR, Koolen KM, van Gemert G-J, van Schaijk B, Leroy D, Sauerwein RW, Bousema T, Dechering KJ. 2015. A semi-automated luminescence based standard membrane feeding assay identifies novel small molecules that inhibit transmission of malaria parasites by mosquitoes. Scientific Reports 5:18704.

89. Hanssen E, Knoechel C, Dearnley M, Dixon MW, Le Gros M, Larabell C, Tilley L. 2012. Soft X-ray microscopy analysis of cell volume and hemoglobin content in erythrocytes infected with asexual and sexual stages of *Plasmodium falciparum*. J Struct Biol 177:224-32.

90. Becker K, Tilley L, Vennerstrom JL, Roberts D, Rogerson S, Ginsburg H. 2004. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int J Parasitol 34:163-89.

91. Zoungrana A, Coulibaly B, Sié A, Walter-Sack I, Mockenhaupt FP, Kouyaté B, Schirmer RH, Klose C, Mansmann U, Meissner P, Müller O. 2008. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated *falciparum* malaria: a randomized controlled trial from Burkina Faso. PLoS ONE 3:e1630.

92. Ohrt C, Li Q, Obaldia N, Im-erbsin R, Xie L, Berman J. 2014. Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria. Malar J 13:415.

93. Ginsburg H, Golenser J. 2003. Glutathione is involved in the antimalarial action of chloroquine and its modulation affects drug sensitivity of human and murine species of *Plasmodium*. Redox Report 8:276-279.

94. Verlinden BK, Niemand J, Snyman J, Sharma SK, Beattie RJ, Woster PM, Birkholtz L. 2011. Discovery of novel alkylated (bis)urea and (bis)thiourea polyamine analogues with potent antimalarial activities. J Med Chem 54:6624-6633.

95. Makler MT, Hinrichs DJ. 1993. Measurement of the lactate dehydrogenase activity of *Plasmodium falciparum* as an assessment of parasitemia. Am J Trop Med Hyg 48:205-210.

96. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48:1803-1806.

97. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.

98. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. 1990. Comparison of *in vitro* anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113-1118.

99. Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH. 2011. Quantitative assessment of *Plasmodium falciparum* sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci USA 108:1214 – 1223.

100. Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W. 2002. Assessment of azithromycin in combination with other antimalarial drugs against *Plasmodium falciparum In Vitro*. Antimicrob Agents Chemother 46:2518-2524.

Table 1: *In vitro* activity of amino artemisinins against asexual *P. falciparum* parasites.

The IC_{50} values for asexual parasites were determined against drug sensitive NF54 or drug resistant Dd2, K1 and W2 parasites using either a metabolic pLDH assay or a proliferative SYBR Green-I based fluorescence assay.

	Asexual IC_{50} (nM)								Cytotoxicity	
	Metabolic readout			Proliferation readout					Viability (%)	EC_{50} (µM)
Cpd	NF54	Dd2	RI[a]	NF54	K1	RI[b]	W2	RI[c]	HepG2[d]	CHO
CQ	31.8±9.9	119.0±20.9	3.7	10±3	154±14	15.4	233±49	23.3	22±0.4 µM (91)	ND
MB	0.3±0.8	12.6±4.0	43.3	5.0±0.8	6.45±0.30	1.29	5.13±0.31	1.03	ND	52.6±4.5
artemisinin	10.8±1.6	17.5±2.5	1.6	0.57±0.01	0.8±0.5	1.40	0.37±0.11	0.65	~90%	ND
DHA	0.8±0.1	5.7±2.0	7.1	2.51±0.19	1.51±0.33	0.60	1.74±0.22	0.69	ND	25.2±3.7
artesunate	10.3±0.8	40.5±5.0	4.0	3.4±0.7	4±1	1.24	2.4±0.4	0.72	~90%	>354
artemether	2.0±0.1	17.3±2.2	8.7	8±1	9±2	1.13	7±1	0.86	~90%	>335
artemisone	3.0±0.8	2.7±0.3	0.9	1.2±0.4	1.01±0.19	0.85	1.6±0.4	1.36	~75%	>249
artemiside	6.0±1.8	8.2±1.4	1.4	1.11±0.17	1.6±0.4	1.47	1.75±0.27	1.58	~80%	>271
10-sulfamide	10.9±3.4	16.9±2.6	1.55	3±1	1.79±0.26	0.56	2.04±0.11	0.64	~90%	56.0±4.6
10-arylamine	7.8±1.9	11.1±1.0	1.41	1.3±0.6	0.64±0.10	0.48	3±1	2.55	~90%	2.9±1.4
10-piperazine	3.2±1.4	1.7±0.2	0.5	3.1±0.4	1.9±0.5	0.61	1.4±0.7	0.45	~77%	ND
10-phenylurea	1.3±0.8	7.5±0.4	5.8	4.7±1.5	2.9±0.6	0.61	1.7±0.5	0.36	~85%	2.4±1.0

Data are means from at least three (n=3) independent biological repeats performed in triplicate for both the metabolic and proliferative assays, ±SEM and a single (n=1) experiment performed in duplicate for cytotoxicity assays on the HepG2 and CHO cell lines, ±SD.

Resistance index (RI): [a]IC_{50} Dd2/ IC_{50} NF54

[b]IC_{50} K1/ IC_{50} NF54

[c]IC_{50} W2/ IC_{50} NF54

[d]% Viability at 1000x IC_{50} against *P. falciparum* parasites

ND=Not determined

Table 2: Activity of amino artemisinins against early (stage I-III) and late (IV/V) stage gametocytes. The IC_{50} values of MB and 10-amino-artemisinins determined against early and late stage gametocytes using the luciferase assay.

	IC_{50} (nM)	
Cpd	**Early stage gametocytes**	**Late stage gametocytes**
MB	95.0±11.3	143.0±16.7
artemisinin	37.0±4.0	77.6±50.0
DHA	43.0±3.9	33.66±1.98
artesunate	37.7±2.0	136.2±85.9
artemether	62.8±3.0	259.4±80.0
artemisone	1.94±0.11	42.4±3.3 [a]
artemiside	16.4±1.0	1.5±0.5 [a]
10-sulfamide	15.0±2.0	419.4±59.5
10-arylamine	38.2±9.0	16.42±6.38
10-piperazine	54.91±5.11	25.7±17.5 [a]
10-phenylurea	83±2	1.70±0.99 [a]

Data are means from at least two independent biological replicates (n=2-4), performed in technical triplicates, ±SEM.

[a]Data are from a 72 h incubation period.

SCHEME AND FIGURE LEGENDS

Scheme 1: (i) DHA, 17.6 mmol, 0.7M in CH_2Cl_2, $(COCl)_2$ (1.1 equiv.), N_2, room temp., 30 min; (ii) solution added to piperazine (52.8 mmol, 3.0 equiv.) in CH_2Cl_2, room temperature, 3 h, 80%; (iii) **3** (1 mmol), Ph-N=C=O (1 mmol), CH_2Cl_2, 24 h, 60%.

Figure 1: (Ai) Formalism indicating irreversible reduction of the oxidant drug artemisinin by reduced conjugates of flavin cofactors flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and other reduced flavins, *e.g.* of riboflavin RF to the inert deoxyartemisinin. **(Aii)** Redox cycling of methylene blue (MB) via its reduced conjugate leucomethylene blue (LMB) initiated through reduction of MB by $FADH_2$ to LMB and re-oxidation of the latter by oxygen to generate MB and reactive oxygen species (ROS). **(B)**: Perturbation of redox-homeostasis by

artemisinin through oxidation of reduced flavin cofactors, e.g. reduced flavin adenine dinucleotide $FADH_2$ of thioredoxin reductase TrxR, glutathione reductase (GR) and other flavin disulfide reductases resulting in build-up of ROS; the artemisinin is thereby irreversibly reduced. Addition of methylene blue (MB) maintains ROS generation via redox cycling through its reduced form leucomethylene blue (LMB) that is oxidized to MB with concomitant generation of ROS; the reduction of MB to LMB by $FADH_2$ is complementary to reduction of artemisinin to deoxyartemisinin by the same reduced cofactor, yet by re-oxidation of the LMB to MB by oxygen, redox cycling now ensues with sustained attrition of $FADH_2$.

Figure 2: Amino artemisinins bearing alkyl- and arylamino groups attached to C10. The oxygen atom attached to C10 in the current clinical artemisinins is replaced by a nitrogen atom.

Figure 3: Gametocytocidal stage-specific and kill kinetic evaluation of compounds against late stage gametocytes: Late stage gametocytes, stage IV/V (10% stage III, 50% stage IV, 40% stage V population) or mature stage V (>95% stage V) were used to determine the differential stage specificity and kill kinetics (speed-of-action) of DHA, artemisone, artemiside, and the 10-arylamine, 10-piperazine and 10-phenylurea between stage IV and V gametocytes. Dose responses were determined using the luciferase reporter lines, exposed to ten-fold serial drug dilutions for 72 h and 72+24 h at 37°C under 90% N_2, 5% CO_2 and 5% O_2 atmospheric conditions. Population compositions were determined microscopically using Giemsa stained smears before (0 h) and after (72 h/72+24 h) incubations for both treated and untreated populations at 2x IC_{50}. Data are the means from a single independent biological experiment with

technical triplicates, error bars indicate ±SD. * = $P<0.05$; ** = $P<0.01$; *** = $P<0.001$, unpaired t-test.

Figure 4: The antiplasmodial activity of 10-amino artemisinins compared to their cross-stage activity and gametocyte stage specificity. Scatter plot of the IC_{50} data of the compounds against asexual, early gametocyte (EG) and late gametocyte stages (LG). The reference compounds (artemisinin, DHA, artesunate and artemether) are indicated in grey-scale and the 10-amino artemisinins in colour. The 10-sulfamide showed consistent loss in activity from asexual to LG stages (purple), like that observed for the reference compounds, whereas artemisone showed EG stage specificity, with a loss in activity towards LG stages (blue). Both artemiside and 10-phenylurea showed LG stage specific 10-amino groups (red and green). Data are means of IC_{50}'s for oxidant compounds for each life cycle stage, *P=0.03 and ***P=0.0002 unpaired t-test.

Figure 5: Isobologram analysis of artemisone and artemiside in combination with MB. Isobolograms were determined using the fixed-ratio isobole analysis method by treating intraerythrocytic asexual stage parasites, early and late stage gametocytes with fixed drug combination ratios (artemisone/artemiside:MB) of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5. Independent dose response curves of fixed drug combinations were determined using the SYBR Green I based assay against intraerythrocytic asexual parasites for 96 h, and the luciferase assay for early and late stage gametocytes at 48 h and 72 h incubations respectively. The dotted lines correspond to an indifferent interaction. The solid line indicates the respective isobole curve of the drug combination. Black lines (circles) represent the SYBR Green assay against asexual

parasites and the luciferase assay against early and late stage gametocytes. The grey line (blocks) represents the pLDH assay against late stage gametocytes for artemisone and MB only. Data are the means from three or four independent biological repeats (n=3/4) performed in technical triplicates, where shown error bars indicate ±SEM.


i.
ii.
iii.
DHA
10-piperazine
10-phenylurea


(Ai)
i: oxidant
oxidized form
Artemisinin
FADH2, FMNH2, RFH2
FAD, FMN, RF
inert reduced form
Deoxy-artemisinin
(Aii)
ii: redox
oxidized form
Methylene Blue (MB)
FADH2
NADPH + GR, TrxR others
FAD
ROS: O2-, H2O2 etc.
O2
Leucomethylene Blue (LMB)
reduced form
(B)
6-phospho-gluconolactone
G6PD
glucose 6-phosphate
NADPH
NADP+
FAD
TrxR GR etc.
FADH2
GSH
GSSG
ROS
H2O
intracellular redox processes
artemisinin methylene blue
Deoxyartemisinin
LMB
GSH
GSSG
MB
Artemisinin
O2
ROS
ROS



Artemisone



Artemiside



10-sulfamide



10-arylamine



10-piperazine



10-phenylurea


DHA
Artemisone
Artemiside
10-arylamine
10-piperazine
10-phenylurea
IV/V V
IC50 (nM)
72 h
72+24 h
Untreated
Gametocytemia (%)
0 h
72 h
72 h+ 24 h
Dead
Stage V
Stage IV
Stage III


*
***
400
200
60
40
20
10
8
6
4
2
0
IC50 (nM)
Asexual
EG
LG
Artemisinin
DHA
Artesunate
Artemether
Artemisone
Artemiside
10-sulfamide
10-arylamine
10-piperazine
10-phenylurea


Asexual parasites
Early stage gametocytes
Late stage gametocytes
FIC50 Artemisone
FIC50 Artemiside
FIC50 MB
0.0
0.5
1.0
1.5